以色列高风险门诊中携带BRCA1/BRCA2致病序列变异的妊娠相关乳腺癌
该研究回顾了以色列最大高风险门诊2014年1月至2021年间263名BRCA致病序列变异携带者的资料,共对292次妊娠行593次乳腺超声、对175名哺乳期携带者行409次乳腺超声。292次妊娠中36次活检4例(PPV=11%)诊断为乳腺癌,均为高级别浸润性癌;175名哺乳期妇女中25次活检2例(PPV=8%)为高级别浸润性癌。妊娠相关乳腺癌发生率为6/292(2.05%),6例中5例为BRCA1携带者、4例为筛查发现,作者认为尽管妊娠哺乳期腺体组织改变,超声可考虑作为该时期高风险患者的筛查工具。
要点
- BRCA携带者妊娠相关乳腺癌发生率为6/292(2.05%),6例中4例为筛查发现。
- 妊娠期乳腺活检PPV为11%(4/36),哺乳期乳腺活检PPV为8%(2/25),均为高级别浸润性癌。
- 6例乳腺癌中5例为BRCA1携带者,作者认为超声可考虑作为妊娠哺乳期高风险患者的筛查工具。
核心结论
- BRCA携带者妊娠相关乳腺癌总体检出率相对较低(2.05%),但仍远高于一般人群;三分之二的乳腺癌由筛查发现,作者认为尽管妊娠哺乳期腺体组织发生改变,筛查对早期发现仍有重要作用,超声可考虑作为该时期高风险患者的筛查工具。
研究设计与样本
- 描述性统计研究,纳入2014年1月至2021年在Meirav高风险门诊连续随访并接受诊断性超声、随访时处于妊娠和/或哺乳期的BRCA致病序列变异携带者,共263名携带者、292次妊娠(593次乳腺超声)和175名哺乳期携带者(409次乳腺超声),参考标准为活检组织学结果。
诊断标准与关键数值
- 妊娠期乳腺活检恶性率(PPV)为11%(4/36),哺乳期乳腺活检PPV为8%(2/25);妊娠相关乳腺癌发生率为6/292(2.05%);6例乳腺癌中5例为BRCA1携带者,4/6为筛查发现。
临床应用与阅片要点
- 作者认为超声可考虑作为BRCA携带者妊娠和哺乳期的筛查工具;原文指出妊娠和哺乳期尚无特异性筛查指南。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Female carriers of pathogenic sequence variants (PSVs) in the BRCA1 /BRCA2 (Breast Cancer gene - BRCA) genes are at a substantially high-risk for developing breast cancer (BC), hence are offered active surveillance scheme based on semiannual breast exam and imaging from age 25 years to facilitate BC early detection (mammography/breast ultrasound depending on the age, and MRI). However, there are not specific guidelines for screening in case of pregnancy or lactation. In the current study, we summarize the experience at the largest high-risk clinic in Israel.
MATERIALS AND METHODS: Data of consecutive BRCA-PSV carriers undergoing surveillance as well as diagnostic ultrasound at the Meirav high-risk clinic from January 2014 to 2021 who were pregnant and/or breastfeeding at time of follow-up were identified. Relevant clinical data including results of breast exam, breast ultrasonography, biopsies and histological results were retrieved. Percentage of biopsies with malignancy, cancer detection rate and positive predictive values were calculated. Data is presented in descriptive statistics.
RESULTS: A total of 263 BRCA-carriers were included. Of these, 593 breast-ultrasonograms were performed in 263 BRCA-carriers for 292 pregnancies and 409 breast-ultrasonograms for 175 breastfeeding carriers. Of 36 breast biopsies in 292 pregnancies, 4 (PPV = 11%) had BC diagnosed (high grade invasive). Of 175 breastfeeding women, 25 biopsies were performed and 2 (PPV = 8%) were high grade invasive BC. Five of 6 BC were diagnosed in BRCA1 carriers, and 4/6 were screen detected. The rate of pregnancy-associated breast cancer was 6/292 (2.05%).
CONCLUSION: The overall detection rate of pregnancy-associated BC in BRCA-carriers is relatively low (2.05%), but still much higher than that in the general population. Two thirds of the BC were detected by screening. Therefore, despite the changes of the glandular breast tissue at time of pregnancy and breastfeeding, screening plays an important role in early detection. Ultrasound should be considered as a screening tool during this period of life of high-risk patients.
引用
- Faermann, Friedman, Kaidar-Person, et al. Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic. Acad Radiol. 2022. PMID: 35527100. doi:10.1016/j.acra.2022.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。